The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
Open accessAbstract
BACKGROUND: We present the combined results of two trials that compared adjuvant chemotherapy with or without concurrent trastuzumab in women with surgically removed HER2-positive breast cancer. METHODS: The National Surgical Adjuvant Breast and Bowel Project trial B-31 compared doxorubicin and cyclophosphamide followed by paclitaxel every 3 weeks (group 1) with the same regimen plus 52 weeks of trastuzumab beginning with the first dose of paclitaxel (group 2). The North Central Cancer Treatment Group trial N9831 compared three regimens: doxorubicin and cyclophosphamide followed by weekly paclitaxel (group A), the same regimen followed by 52 weeks of trastuzumab after paclitaxel (group B), and the same regimen plus 52 weeks of trastuzumab initiated concomitantly with paclitaxel (group C). The studies were amended to include a joint analysis comparing groups 1 and A (the control group) with groups 2 and C (the trastuzumab group). Group B was excluded because trastuzumab was not given concurrently with paclitaxel. RESULTS: By March 15, 2005, 394 events (recurrent, second primary cancer, or death before recurrence) had been reported, triggering the first scheduled interim analysis. Of these, 133 were in the trastuzumab group and 261 in the control group (hazard ratio, 0.48; P<0.0001). This result crossed the early stopping boundary. The absolute difference in disease-free survival between the trastuzumab group and the control group was 12 percent at three years. Trastuzumab therapy was associated with a 33 percent reduction in the risk of death (P=0.015). The three-year cumulative incidence of class III or IV congestive heart failure or death from cardiac causes in the trastuzumab group was 4.1 percent in trial B-31 and 2.9 percent in trial N9831. CONCLUSIONS: Trastuzumab combined with paclitaxel after doxorubicin and cyclophosphamide improves outcomes among women with surgically removed HER2-positive breast cancer. (ClinicalTrials.gov numbers, NCT00004067 and NCT00005970.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Pocock, S. J., & Simon, R. (1975) · Biometrics · doi:10.2307/2529712 · Cited by 2,350
Cardiac Dysfunction in the Trastuzumab Clinical Trials Experience
Seidman, A. D., Hudis, C. A., Pierri, M. K., Shak, S., Paton, V. E., Ashby, M. A., Murphy, M., Stewart, S. J., & Keefe, D. L. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.5.1215 · Cited by 1,563
Bendell, J. C., Domchek, S. M., Burstein, H. J., Harris, L., Younger, J., Kuter, I., Bunnell, C., Rue, M., Gelman, R., & Winer, E. (2003) · Cancer · doi:10.1002/cncr.11436 · Cited by 1,320
Tan-Chiu, E., Yothers, G., Romond, E., Geyer, C. E., Ewer, M., Keefe, D., Shannon, R. P., Swain, S. M., Brown, A., Fehrenbacher, L., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.4091 · Cited by 808
Self-citationForest plots: trying to see the wood and the trees
Lewis, S., & Clarke, M. (2001) · BMJ · doi:10.1136/bmj.322.7300.1479 · Cited by 763
CNS Metastases in Breast Cancer
Lin, N. U., Bellon, J. R., & Winer, E. P. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.01.175 · Cited by 715
Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer
Clayton, A. J., Danson, S., Jolly, S., Ryder, W. D. J., Burt, P. A., Stewart, A. L., Wilkinson, P. M., Welch, R. S., Magee, B., Wilson, G., et al. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601970 · Cited by 385
Research works printed but not linked: 2
- Albain KS, 2002, Proc Am Soc Clin Oncol, 21, 37A abstract
- Ewer MS, 2002, Proc Am Soc Clin Oncol, 21, 123A
Cited by
Items 101–200 of 319
Antibody tumor penetration: Transport opposed by systemic and antigen-mediated clearance
Thurber, G. M., Schmidt, M. M., & Wittrup, K. D. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2008.04.012 · Cited by 624
Scheuer, W., Friess, T., Burtscher, H., Bossenmaier, B., Endl, J., & Hasmann, M. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4597 · Cited by 622
Moran, M. S., Schnitt, S. J., Giuliano, A. E., Harris, J. R., Khan, S. A., Horton, J., Klimberg, S., Chavez-MacGregor, M., Freedman, G., Houssami, N., et al. (2014) · Annals of Surgical Oncology · doi:10.1245/s10434-014-3481-4 · Cited by 612
Gianni, L., Dafni, U., Gelber, R. D., Azambuja, E., Muehlbauer, S., Goldhirsch, A., Untch, M., Smith, I., Baselga, J., Jackisch, C., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70033-x · Cited by 612
HER2 and Response to Paclitaxel in Node-Positive Breast Cancer
Hayes, D. F., Thor, A. D., Dressler, L. G., Weaver, D., Edgerton, S., Cowan, D., Broadwater, G., Goldstein, L. J., Martino, S., Ingle, J. N., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa071167 · Cited by 608
Self-citationTrastuzumab containing regimens for early breast cancer
Moja, L., Tagliabue, L., Balduzzi, S., Parmelli, E., Pistotti, V., Guarneri, V., & D'Amico, R. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006243.pub2 · Cited by 604
HER2 testing in gastric cancer: a practical approach
Rüschoff, J., Hanna, W., Bilous, M., Hofmann, M., Osamura, R. Y., Penault-Llorca, F., van de Vijver, M., & Viale, G. (2012) · Modern Pathology · doi:10.1038/modpathol.2011.198 · Cited by 595
Seidman, A. D., Berry, D., Cirrincione, C., Harris, L., Muss, H., Marcom, P. K., Gipson, G., Burstein, H., Lake, D., Shapiro, C. L., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.6699 · Cited by 594
Breast Cancer—Epidemiology, Classification, Pathogenesis and Treatment (Review of Literature)
Smolarz, B., Nowak, A. Z., & Romanowicz, H. (2022) · Cancers · doi:10.3390/cancers14102569 · Cited by 587
The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity
Park, S., Jiang, Z., Mortenson, E. D., Deng, L., Radkevich-Brown, O., Yang, X., Sattar, H., Wang, Y., Brown, N. K., Greene, M., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.06.014 · Cited by 577
“Based on the convincing preclinical studies, clinical trials were conducted and demonstrated the benefits of combining chemotherapy administration with trastuzumab (Hudis, 2007; Piccart-Gebhart et al., 2005; Romond et al., 2005).”
BackgroundEmerging use of nanoparticles in diagnosis and treatment of breast cancer
Yezhelyev, M. V., Gao, X., Xing, Y., Al-Hajj, A., Nie, S., & O'Regan, R. M. (2006) · The Lancet Oncology · doi:10.1016/s1470-2045(06)70793-8 · Cited by 577
ErbB receptors: from oncogenes to targeted cancer therapies
Zhang, H., Berezov, A., Wang, Q., Zhang, G., Drebin, J., Murali, R., & Greene, M. I. (2007) · Journal of Clinical Investigation · doi:10.1172/jci32278 · Cited by 574
Trastuzumab-Associated Cardiac Adverse Effects in the Herceptin Adjuvant Trial
Suter, T. M., Procter, M., van Veldhuisen, D. J., Muscholl, M., Bergh, J., Carlomagno, C., Perren, T., Passalacqua, R., Bighin, C., Klijn, J. G. M., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.1611 · Cited by 566
Bowles, E. J. A., Wellman, R., Feigelson, H. S., Onitilo, A. A., Freedman, A. N., Delate, T., Allen, L. A., Nekhlyudov, L., Goddard, K. A. B., Davis, R. L., et al. (2012) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djs317 · Cited by 566
Chan, A., Delaloge, S., Holmes, F. A., Moy, B., Iwata, H., Harvey, V. J., Robert, N. J., Silovski, T., Gokmen, E., von Minckwitz, G., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00551-3 · Cited by 561
Untch, M., Rezai, M., Loibl, S., Fasching, P. A., Huober, J., Tesch, H., Bauerfeind, I., Hilfrich, J., Eidtmann, H., Gerber, B., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.8451 · Cited by 556
The role of HER2 in cancer therapy and targeted drug delivery
Tai, W., Mahato, R., & Cheng, K. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.04.009 · Cited by 555
Overview of Breast Cancer Therapy
Moo, T.-A., Sanford, R., Dang, C., & Morrow, M. (2018) · PET Clinics · doi:10.1016/j.cpet.2018.02.006 · Cited by 551
Junttila, T. T., Li, G., Parsons, K., Phillips, G. L., & Sliwkowski, M. X. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-1090-x · Cited by 541
The Distinctive Nature of HER2-Positive Breast Cancers
Burstein, H. J. (2005) · New England Journal of Medicine · doi:10.1056/nejmp058197 · Cited by 541
Jones, S. E., Savin, M. A., Holmes, F. A., O'Shaughnessy, J. A., Blum, J. L., Vukelja, S., McIntyre, K. J., Pippen, J. E., Bordelon, J. H., Kirby, R., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.5391 · Cited by 538
Perez, E. A., Suman, V. J., Davidson, N. E., Sledge, G. W., Kaufman, P. A., Hudis, C. A., Martino, S., Gralow, J. R., Dakhil, S. R., Ingle, J. N., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.5467 · Cited by 538
Self-citationTaxanes, microtubules and chemoresistant breast cancer
McGrogan, B. T., Gilmartin, B., Carney, D. N., & McCann, A. (2008) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2007.10.004 · Cited by 535
Houssami, N., Macaskill, P., Luke Marinovich, M., & Morrow, M. (2014) · Annals of Surgical Oncology · doi:10.1245/s10434-014-3480-5 · Cited by 532
Burstein, H. J., Sun, Y., Dirix, L. Y., Jiang, Z., Paridaens, R., Tan, A. R., Awada, A., Ranade, A., Jiao, S., Schwartz, G., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.8707 · Cited by 522
Romond, E. H., Jeong, J.-H., Rastogi, P., Swain, S. M., Geyer, C. E., Ewer, M. S., Rathi, V., Fehrenbacher, L., Brufsky, A., Azar, C. A., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.0010 · Cited by 520
Self-citationThe HER2 Receptor in Breast Cancer: Pathophysiology, Clinical Use, and New Advances in Therapy
Mitri, Z., Constantine, T., & O'Regan, R. (2012) · Chemotherapy Research and Practice · doi:10.1155/2012/743193 · Cited by 519
Zhang, S., Huang, W.-C., Li, P., Guo, H., Poh, S.-B., Brady, S. W., Xiong, Y., Tseng, L.-M., Li, S.-H., Ding, Z., et al. (2011) · Nature Medicine · doi:10.1038/nm.2309 · Cited by 515
An overview of prognostic factors for long-term survivors of breast cancer
Soerjomataram, I., Louwman, M. W. J., Ribot, J. G., Roukema, J. A., & Coebergh, J. W. W. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9556-1 · Cited by 513
Sauter, G., Lee, J., Bartlett, J. M. S., Slamon, D. J., & Press, M. F. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.8197 · Cited by 509
Lyon, A. R., López-Fernández, T., Couch, L. S., Asteggiano, R., Aznar, M. C., Bergler-Klein, J., Boriani, G., Cardinale, D., Cordoba, R., Cosyns, B., et al. (2022) · European Heart Journal - Cardiovascular Imaging · doi:10.1093/ehjci/jeac106 · Cited by 507
Untch, M., Fasching, P. A., Konecny, G. E., Hasmüller, S., Lebeau, A., Kreienberg, R., Camara, O., Müller, V., du Bois, A., Kühn, T., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.4930 · Cited by 506
Resistance to Trastuzumab in Breast Cancer
Pohlmann, P. R., Mayer, I. A., & Mernaugh, R. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0636 · Cited by 505
Cancer biomarker discovery and validation.
Goossens, N., Nakagawa, S., Sun, X., & Hoshida, Y. (2015) · PubMed · doi:10.3978/j.issn.2218-676x.2015.06.04 · Cited by 503
Ritter, C. A., Perez-Torres, M., Rinehart, C., Guix, M., Dugger, T., Engelman, J. A., & Arteaga, C. L. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0701 · Cited by 497
Goldhirsch, A., Gelber, R. D., Piccart-Gebhart, M. J., de Azambuja, E., Procter, M., Suter, T. M., Jackisch, C., Cameron, D., Weber, H. A., Heinzmann, D., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61094-6 · Cited by 497
Spector, N. L., & Blackwell, K. L. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.1507 · Cited by 497
Current and emerging biomarkers in breast cancer: prognosis and prediction
Weigel, M. T., & Dowsett, M. (2010) · Endocrine-Related Cancer · doi:10.1677/erc-10-0136 · Cited by 496
Moran, M. S., Schnitt, S. J., Giuliano, A. E., Harris, J. R., Khan, S. A., Horton, J., Klimberg, S., Chavez-MacGregor, M., Freedman, G., Houssami, N., et al. (2014) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2013.11.012 · Cited by 495
HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies
Gajria, D., & Chandarlapaty, S. (2011) · Expert Review of Anticancer Therapy · doi:10.1586/era.10.226 · Cited by 494
Gianni, L., Eiermann, W., Semiglazov, V., Lluch, A., Tjulandin, S., Zambetti, M., Moliterni, A., Vazquez, F., Byakhov, M. J., Lichinitser, M., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70080-4 · Cited by 490
Rüschoff, J., Dietel, M., Baretton, G., Arbogast, S., Walch, A., Monges, G., Chenard, M.-P., Penault-Llorca, F., Nagelmeier, I., Schlake, W., et al. (2010) · Virchows Archiv · doi:10.1007/s00428-010-0952-2 · Cited by 486
Fallah-Rad, N., Walker, J. R., Wassef, A., Lytwyn, M., Bohonis, S., Fang, T., Tian, G., Kirkpatrick, I. D. C., Singal, P. K., Krahn, M., et al. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.11.063 · Cited by 484
HER2 expression status in diverse cancers: review of results from 37,992 patients
Yan, M., Schwaederle, M., Arguello, D., Millis, S. Z., Gatalica, Z., & Kurzrock, R. (2015) · Cancer and Metastasis Reviews · doi:10.1007/s10555-015-9552-6 · Cited by 483
Targeted nanoparticles for cancer therapy
Gu, F. X., Karnik, R., Wang, A. Z., Alexis, F., Levy-Nissenbaum, E., Hong, S., Langer, R. S., & Farokhzad, O. C. (2007) · Nano Today · doi:10.1016/s1748-0132(07)70083-x · Cited by 478
Targeting Tyrosine Kinases in Cancer: The Second Wave
Baselga, J. (2006) · Science · doi:10.1126/science.1125951 · Cited by 478
Buzdar, A. U., Valero, V., Ibrahim, N. K., Francis, D., Broglio, K. R., Theriault, R. L., Pusztai, L., Green, M. C., Singletary, S. E., Hunt, K. K., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1345 · Cited by 475
A review on machine learning approaches and trends in drug discovery
Carracedo-Reboredo, P., Liñares-Blanco, J., Rodríguez-Fernández, N., Cedrón, F., Novoa, F. J., Carballal, A., Maojo, V., Pazos, A., & Fernandez-Lozano, C. (2021) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2021.08.011 · Cited by 472
Booth, C. M., & Tannock, I. F. (2014) · British Journal of Cancer · doi:10.1038/bjc.2013.725 · Cited by 469
Gonzalez-Angulo, A. M., Litton, J. K., Broglio, K. R., Meric-Bernstam, F., Rakkhit, R., Cardoso, F., Peintinger, F., Hanrahan, E. O., Sahin, A., Guray, M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.2025 · Cited by 467
Current Trends in Postmastectomy Breast Reconstruction
Panchal, H., & Matros, E. (2017) · Plastic & Reconstructive Surgery · doi:10.1097/prs.0000000000003941 · Cited by 462
Fabrication of gold nanoparticles for targeted therapy in pancreatic cancer
Patra, C. R., Bhattacharya, R., Mukhopadhyay, D., & Mukherjee, P. (2010) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.11.007 · Cited by 458
Joensuu, H., Bono, P., Kataja, V., Alanko, T., Kokko, R., Asola, R., Utriainen, T., Turpeenniemi-Hujanen, T., Jyrkkiö, S., Möykkynen, K., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.4577 · Cited by 458
de Azambuja, E., Holmes, A. P., Piccart-Gebhart, M., Holmes, E., Di Cosimo, S., Swaby, R. F., Untch, M., Jackisch, C., Lang, I., Smith, I., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70320-1 · Cited by 458
Self-citationLin, N. U., Carey, L. A., Liu, M. C., Younger, J., Come, S. E., Ewend, M., Harris, G. J., Bullitt, E., Van den Abbeele, A. D., Henson, J. W., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.3588 · Cited by 456
Genetic heterogeneity and cancer drug resistance
Turner, N. C., & Reis-Filho, J. S. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70335-7 · Cited by 454
Negishi, K., Negishi, T., Hare, J. L., Haluska, B. A., Plana, J. C., & Marwick, T. H. (2013) · Journal of the American Society of Echocardiography · doi:10.1016/j.echo.2013.02.008 · Cited by 454
Age, Breast Cancer Subtype Approximation, and Local Recurrence After Breast-Conserving Therapy
Arvold, N. D., Taghian, A. G., Niemierko, A., Abi Raad, R. F., Sreedhara, M., Nguyen, P. L., Bellon, J. R., Wong, J. S., Smith, B. L., & Harris, J. R. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.1105 · Cited by 452
Moran, M. S., Schnitt, S. J., Giuliano, A. E., Harris, J. R., Khan, S. A., Horton, J., Klimberg, S., Chavez-MacGregor, M., Freedman, G., Houssami, N., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.3935 · Cited by 451
Carlson, R. W., Allred, D. C., Anderson, B. O., Burstein, H. J., Carter, W. B., Edge, S. B., Erban, J. K., Farrar, W. B., Goldstein, L. J., Gradishar, W. J., et al. (2009) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2009.0012 · Cited by 450
Molecular Subtypes and Local-Regional Control of Breast Cancer
Fragomeni, S. M., Sciallis, A., & Jeruss, J. S. (2018) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2017.08.005 · Cited by 450
Early Breast Cancer Therapy and Cardiovascular Injury
Jones, L. W., Haykowsky, M. J., Swartz, J. J., Douglas, P. S., & Mackey, J. R. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.06.037 · Cited by 447
Scaltriti, M., Verma, C., Guzman, M., Jimenez, J., Parra, J. L., Pedersen, K., Smith, D. J., Landolfi, S., Ramon y Cajal, S., Arribas, J., et al. (2009) · Oncogene · doi:10.1038/onc.2008.432 · Cited by 439
Perez, E. A., Suman, V. J., Davidson, N. E., Martino, S., Kaufman, P. A., Lingle, W. L., Flynn, P. J., Ingle, J. N., Visscher, D., & Jenkins, R. B. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.4744 · Cited by 438
Self-citationEsserman, L. J., Berry, D. A., DeMichele, A., Carey, L., Davis, S. E., Buxton, M., Hudis, C., Gray, J. W., Perou, C., Yau, C., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.2779 · Cited by 438
Immunotherapy of cancer in 2012
Kirkwood, J. M., Butterfield, L. H., Tarhini, A. A., Zarour, H., Kalinski, P., & Ferrone, S. (2012) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20132 · Cited by 436
HER2 therapy: Molecular mechanisms of trastuzumab resistance
Nahta, R., & Esteva, F. J. (2006) · Breast Cancer Research · doi:10.1186/bcr1612 · Cited by 433
Geiger, T. R., & Peeper, D. S. (2009) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2009.07.006 · Cited by 431
HER2 Status and Benefit from Adjuvant Trastuzumab in Breast Cancer
Paik, S., Kim, C., & Wolmark, N. (2008) · New England Journal of Medicine · doi:10.1056/nejmc0801440 · Cited by 426
Self-citationModi, S., Stopeck, A., Linden, H., Solit, D., Chandarlapaty, S., Rosen, N., D'Andrea, G., Dickler, M., Moynahan, M. E., Sugarman, S., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0072 · Cited by 424
Tumor Microenvironment and Differential Responses to Therapy
Hirata, E., & Sahai, E. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026781 · Cited by 422
Brain Metastases: The HER2 Paradigm
Lin, N. U., & Winer, E. P. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2478 · Cited by 417
Nanoparticles and their applications in cell and molecular biology
Wang, E. C., & Wang, A. Z. (2014) · Integrative Biology · doi:10.1039/c3ib40165k · Cited by 415
Eschenhagen, T., Force, T., Ewer, M. S., de Keulenaer, G. W., Suter, T. M., Anker, S. D., Avkiran, M., de Azambuja, E., Balligand, J.-L., Brutsaert, D. L., et al. (2011) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfq213 · Cited by 413
Finn, R. S., Dering, J., Ginther, C., Wilson, C. A., Glaspy, P., Tchekmedyian, N., & Slamon, D. J. (2007) · Breast Cancer Research and Treatment · doi:10.1007/s10549-006-9463-x · Cited by 409
Houssami, N., Macaskill, P., Marinovich, M. L., Dixon, J. M., Irwig, L., Brennan, M. E., & Solin, L. J. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.07.043 · Cited by 406
Fehrenbacher, L., Cecchini, R. S., Geyer Jr, C. E., Rastogi, P., Costantino, J. P., Atkins, J. N., Crown, J. P., Polikoff, J., Boileau, J.-F., Provencher, L., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.01455 · Cited by 404
Self-citationMandrekar, S. J., & Sargent, D. J. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.3701 · Cited by 404
Aeffner, F., Zarella, M. D., Buchbinder, N., Bui, M. M., Goodman, M. R., Hartman, D. J., Lujan, G. M., Molani, M. A., Parwani, A. V., Lillard, K., et al. (2019) · Journal of Pathology Informatics · doi:10.4103/jpi.jpi_82_18 · Cited by 403
Bodai, B. I., & Tuso, P. (2015) · The Permanente Journal · doi:10.7812/tpp/14-241 · Cited by 397
Harris, E. E. R., Correa, C., Hwang, W.-T., Liao, J., Litt, H. I., Ferrari, V. A., & Solin, L. J. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.1037 · Cited by 393
Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA
Lund, M. J., Trivers, K. F., Porter, P. L., Coates, R. J., Leyland-Jones, B., Brawley, O. W., Flagg, E. W., O’Regan, R. M., Gabram, S. G. A., & Eley, J. W. (2009) · Breast Cancer Research and Treatment · doi:10.1007/s10549-008-9926-3 · Cited by 390
Locoregional recurrence after breast cancer surgery: a systematic review by receptor phenotype
Lowery, A. J., Kell, M. R., Glynn, R. W., Kerin, M. J., & Sweeney, K. J. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1891-6 · Cited by 389
Cardiac Safety of Lapatinib: Pooled Analysis of 3689 Patients Enrolled in Clinical Trials
Perez, E. A., Koehler, M., Byrne, J., Preston, A. J., Rappold, E., & Ewer, M. S. (2008) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(11)60896-3 · Cited by 388
Self-citationRobidoux, A., Tang, G., Rastogi, P., Geyer, C. E., Azar, C. A., Atkins, J. N., Fehrenbacher, L., Bear, H. D., Baez-Diaz, L., Sarwar, S., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70411-x · Cited by 386
Self-citationSelective in vivo metabolic cell-labeling-mediated cancer targeting
Wang, H., Wang, R., Cai, K., He, H., Liu, Y., Yen, J., Wang, Z., Xu, M., Sun, Y., Zhou, X., et al. (2017) · Nature Chemical Biology · doi:10.1038/nchembio.2297 · Cited by 386
Trastuzumab-Related Cardiotoxicity: Calling Into Question the Concept of Reversibility
Telli, M. L., Hunt, S. A., Carlson, R. W., & Guardino, A. E. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.0106 · Cited by 385
Xu, J., Chen, Y., & Olopade, O. I. (2010) · Genes & Cancer · doi:10.1177/1947601910378691 · Cited by 382
Viani, G. A., Afonso, S. L., Stefano, E. J., De Fendi, L. I., & Soares, F. V. (2007) · BMC Cancer · doi:10.1186/1471-2407-7-153 · Cited by 381
Hussain, M. H. A., MacVicar, G. R., Petrylak, D. P., Dunn, R. L., Vaishampayan, U., Lara, P. N., Chatta, G. S., Nanus, D. M., Glode, L. M., Trump, D. L., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.0994 · Cited by 376
Effects of Age on the Detection and Management of Breast Cancer
McGuire, A., Brown, J., Malone, C., McLaughlin, R., & Kerin, M. (2015) · Cancers · doi:10.3390/cancers7020815 · Cited by 374
Current issues in ER and HER2 testing by IHC in breast cancer
Gown, A. M. (2008) · Modern Pathology · doi:10.1038/modpathol.2008.34 · Cited by 374
Progress in adjuvant chemotherapy for breast cancer: an overview
Anampa, J., Makower, D., & Sparano, J. A. (2015) · BMC Medicine · doi:10.1186/s12916-015-0439-8 · Cited by 373
Principles and methods of integrative genomic analyses in cancer
Kristensen, V. N., Lingjærde, O. C., Russnes, H. G., Vollan, H. K. M., Frigessi, A., & Børresen-Dale, A.-L. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3721 · Cited by 371
Piccart-Gebhart, M., Holmes, E., Baselga, J., de Azambuja, E., Dueck, A. C., Viale, G., Zujewski, J. A., Goldhirsch, A., Armour, A., Pritchard, K. I., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.1797 · Cited by 371
Self-citationSperduto, P. W., Kased, N., Roberge, D., Xu, Z., Shanley, R., Luo, X., Sneed, P. K., Chao, S. T., Weil, R. J., Suh, J., et al. (2012) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2011.02.027 · Cited by 371
Rexer, B. N., & Arteaga, C. L. (2012) · Critical Reviews™ in Oncogenesis · doi:10.1615/critrevoncog.v17.i1.20 · Cited by 370
Putative DNA/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agents
Zoppoli, G., Regairaz, M., Leo, E., Reinhold, W. C., Varma, S., Ballestrero, A., Doroshow, J. H., & Pommier, Y. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1205943109 · Cited by 369
Targeted therapies for breast cancer
Higgins, M. J., & Baselga, J. (2011) · Journal of Clinical Investigation · doi:10.1172/jci57152 · Cited by 369
Goldstein, L. J., Gray, R., Badve, S., Childs, B. H., Yoshizawa, C., Rowley, S., Shak, S., Baehner, F. L., Ravdin, P. M., Davidson, N. E., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.4501 · Cited by 369
Self-citation
Metadata
- Authors
- Romond, E. H., Perez, E. A., Bryant, J., Suman, V. J., Geyer, C. E., Davidson, N. E., Tan-Chiu, E., Martino, S., Paik, S., Kaufman, P. A., Swain, S. M., Pisansky, T. M., Fehrenbacher, L., Kutteh, L. A., Vogel, V. G., Visscher, D. W., Yothers, G., Jenkins, R. B., Brown, A. M., Dakhil, S. R., Mamounas, E. P., Lingle, W. L., Klein, P. M., Ingle, J. N., & Wolmark, N.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2005-10-20
- Volume
- 353
- Issue
- 16
- Pages
- 1673-1684
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2146384083
- Cited by
- 5,356
- References
- 12
- FWCI
- 148.53
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.